Showing 121 to 132 of 152 results
AstraZeneca's Q4 2024 Earnings Exceed Expectations, Driven by Strong Clinical Trial Results
AstraZeneca announced strong Q4 2024 and full-year results, with total revenue surging 24% to $14.9 billion in Q4 and 18% to $54.1 billion for the full year, driven by successful clinical trials and rising demand across all major therapy areas; CEO Pascal Soriot highlighted this as the start of a ca...
AstraZeneca's Q4 2024 Earnings Exceed Expectations, Driven by Strong Clinical Trial Results
AstraZeneca announced strong Q4 2024 and full-year results, with total revenue surging 24% to $14.9 billion in Q4 and 18% to $54.1 billion for the full year, driven by successful clinical trials and rising demand across all major therapy areas; CEO Pascal Soriot highlighted this as the start of a ca...
Progress
56% Bias Score
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Progress
40% Bias Score
Labour's AstraZeneca Snub Threatens UK Science Hub Ambitions
Labour's refusal to support AstraZeneca's £450 million Liverpool vaccine plant clashes with their science goals, contrasting with US government support and potentially driving investment away from the UK.
Labour's AstraZeneca Snub Threatens UK Science Hub Ambitions
Labour's refusal to support AstraZeneca's £450 million Liverpool vaccine plant clashes with their science goals, contrasting with US government support and potentially driving investment away from the UK.
Progress
64% Bias Score
Walgreens Suspends Dividend After 90+ Years, Stock Plunges 11%
Walgreens Boots Alliance Inc. suspended its dividend after more than 90 years, causing an 11% stock drop in premarket trading due to financial challenges including legal issues, rising costs, and reduced consumer spending; the company plans to close 1200 stores.
Walgreens Suspends Dividend After 90+ Years, Stock Plunges 11%
Walgreens Boots Alliance Inc. suspended its dividend after more than 90 years, causing an 11% stock drop in premarket trading due to financial challenges including legal issues, rising costs, and reduced consumer spending; the company plans to close 1200 stores.
Progress
40% Bias Score
Europe's Slow Progress Towards Pharmaceutical Sovereignty
Europe's pharmaceutical supply chain is vulnerable due to reliance on distant countries for raw materials and production; this has led to shortages of essential medicines, prompting calls for higher drug prices and increased domestic production.
Europe's Slow Progress Towards Pharmaceutical Sovereignty
Europe's pharmaceutical supply chain is vulnerable due to reliance on distant countries for raw materials and production; this has led to shortages of essential medicines, prompting calls for higher drug prices and increased domestic production.
Progress
40% Bias Score
Record Irish Tax Revenue: A Windfall Threatened by US Policies
Ireland's 2023 tax revenue hit a record \$108 billion, a 23% increase driven by Apple's \$11 billion tax payment and rising income tax. However, this prosperity is threatened by potential US tariffs and tax code changes.
Record Irish Tax Revenue: A Windfall Threatened by US Policies
Ireland's 2023 tax revenue hit a record \$108 billion, a 23% increase driven by Apple's \$11 billion tax payment and rising income tax. However, this prosperity is threatened by potential US tariffs and tax code changes.
Progress
48% Bias Score
Widespread Fraud Delays Alzheimer's Cure
Investigative journalist Charles Piller's book, "Doctored," exposes widespread fraud in Alzheimer's research, revealing fabricated results, manipulated images, and regulatory failures costing hundreds of millions of dollars and delaying potential cures; the cases of Lesné and Ashe, and Cassava Scien...
Widespread Fraud Delays Alzheimer's Cure
Investigative journalist Charles Piller's book, "Doctored," exposes widespread fraud in Alzheimer's research, revealing fabricated results, manipulated images, and regulatory failures costing hundreds of millions of dollars and delaying potential cures; the cases of Lesné and Ashe, and Cassava Scien...
Progress
48% Bias Score
Medical Malpractice and Overbilling Cause Texas Woman's Death
A Texas woman died during a medically negligent procedure at Integrity Wellness (now Cedarwood Surgical Center) due to anesthesia errors and inadequate monitoring; the clinic also engaged in extreme overbilling.
Medical Malpractice and Overbilling Cause Texas Woman's Death
A Texas woman died during a medically negligent procedure at Integrity Wellness (now Cedarwood Surgical Center) due to anesthesia errors and inadequate monitoring; the clinic also engaged in extreme overbilling.
Progress
48% Bias Score
US-EU Trade Conflict Threatens German Pharmaceutical Industry
A potential US-EU trade conflict under Donald Trump significantly threatens Germany's pharmaceutical industry, which exported \$26 billion worth of drugs to the US in 2023, making the US its most important export market and supplier of raw materials. This dependence raises concerns about potential d...
US-EU Trade Conflict Threatens German Pharmaceutical Industry
A potential US-EU trade conflict under Donald Trump significantly threatens Germany's pharmaceutical industry, which exported \$26 billion worth of drugs to the US in 2023, making the US its most important export market and supplier of raw materials. This dependence raises concerns about potential d...
Progress
44% Bias Score
Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.
Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints
Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.
Progress
36% Bias Score
Canadian Court Certifies Class-Action Lawsuit Against Opioid Companies
A British Columbia Supreme Court judge certified a class-action lawsuit against over 40 opioid companies for allegedly over-promoting prescription opioid use, leading to substantial public health care costs; the B.C. government, joined by all other Canadian governments, alleges wrongful conduct and ...
Canadian Court Certifies Class-Action Lawsuit Against Opioid Companies
A British Columbia Supreme Court judge certified a class-action lawsuit against over 40 opioid companies for allegedly over-promoting prescription opioid use, leading to substantial public health care costs; the B.C. government, joined by all other Canadian governments, alleges wrongful conduct and ...
Progress
44% Bias Score
Healthcare Sector Lags Despite Innovation, Poised for Growth
The healthcare sector, particularly biotech, is underperforming despite promising innovations due to investor apathy and post-pandemic market corrections; however, experts anticipate future growth fueled by technological advancements, demographic shifts, and potential deregulation.
Healthcare Sector Lags Despite Innovation, Poised for Growth
The healthcare sector, particularly biotech, is underperforming despite promising innovations due to investor apathy and post-pandemic market corrections; however, experts anticipate future growth fueled by technological advancements, demographic shifts, and potential deregulation.
Progress
56% Bias Score
Showing 121 to 132 of 152 results